Following on from information provided to NICE by the company in November 2005 the appraisal of Venous thromboembolism (recurrent) - idraparinux sodium [ID395] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 395 |
| Referral date | 01 November 2005 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| Final scope published: | TBC |
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting | TBC |
| 3rd appraisal committee meeting: | TBC |
| 4th appraisal committee meeting: | TBC |
| 5th appraisal committee meeting: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 January 2023 | Discontinued. Following on from information provided to NICE by the company in November 2005 the appraisal of Venous thromboembolism (recurrent) - idraparinux sodium [ID395] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 25 August 2006 | This topic was referred by the Department of Health and the Welsh Assembly Government as part of the Institute's 12th wave work programme. |
| 23 July 2007 |
Idraparinux sodium for the treatment of venous thromboembolism The manufacturer of idraparinux sodium has advised us that the regulatory strategy in relation to this product is not finalised. The Institute has therefore decided to remove this appraisal from its work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. 19 July 2007 |
For further information on our processes and methods, please see our CHTE processes and methods manual